Jove
Visualize
联系我们

相关概念视频

Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

1.9K
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
1.9K
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.6K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.6K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

231
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
231
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

314
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
314
Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

1.0K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
1.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Randomization and allocation procedures for master protocol trials of single-arm studies.

Statistical methods in medical research·2026
Same author

A note on phase I interleaved versus parallel group ascending dose designs for concentration-QTc analyses.

Journal of pharmacokinetics and pharmacodynamics·2025
Same author

Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Using Confidence Distributions in Final and Interim Analyses for Single-Arm Studies or Platform Trials Consisting of Single-Arm Studies.

Statistics in medicine·2025
Same author

Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.

Neuro-oncology practice·2024
Same author

First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.

Clinical and translational science·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 14, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.5K

对几种活性化合物的QT数据进行度响应分析.

Günter Heimann1, Giulia Lestini2, Jochen Zisowsky3

  • 1Advanced Quantitative Sciences / Pharmacometrics, Novartis Pharma AG, Fabrikstrasse 2, Basel, 4002, Switzerland. guenter.heimann@gmx.de.

Journal of pharmacokinetics and pharmacodynamics
|January 12, 2026
PubMed
概括
此摘要是机器生成的。

这项研究引入了一种新的药物开发方法,联合建模多种活性化合物,以评估它们对纠正的QT (QTc) 间隔的影响. 该方法提供了一个正式的假设测试,以排除5毫秒的QTc效应,改善安全评估.

关键词:
活性代谢物活性代谢物.在 Bootstrap 中使用 Bootstrap.药物组合是一种药物组合.度-QTc分析的分析

更多相关视频

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.7K

相关实验视频

Last Updated: Jan 14, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.5K
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.7K

科学领域:

  • 药理动力学和药理动力学
  • 药物安全与毒理学
  • 在药物开发中的统计建模.

背景情况:

  • 药理动力学-药理动力学 (PK-QTc) 分析是药物开发中的标准,通常评估单个化合物.
  • 多种活性化合物 (例如原始药物,代谢物,组合疗法) 可以使PK-QTc评估复杂化.
  • 以前的研究表明,对每个化合物的单独分析可以产生偏差的结果,主张联合建模.

研究的目的:

  • 提出一种正式的假设测试,以排除5毫秒校正的QT (QTc) 间隔效应,使用两个活性化合物的联合建模.
  • 将现有的PK-QTc分析方法扩展到涉及多个相互作用化合物的场景.
  • 为复杂的药理学资料中药物安全性评估提供统计学上可靠的方法.

主要方法:

  • 开发了一种联合建模方法,用于测量两种潜在活性化合物对QTc间隔的影响.
  • 提出了一个正式的假设测试,利用关键参数的上置信区间 ([公式:见文本],[公式:见文本],[公式:见文本]) 来排除5毫秒的QTc效应.
  • 采用启动式决策方法,并通过模拟验证该方法以控制5%的I型错误.

主要成果:

  • 拟议的联合建模和假设测试方法有效控制了模拟中的5%的I型错误率.
  • 该方法成功排除了5毫秒的QTc效应,当所有三个上置信限都低于值时.
  • 该方法被证明用于线性暴露-反应关系,并且可以适应非线性情景.

结论:

  • 在多种活性化合物存在时,联合建模可以更准确地评估QTc间隔效应.
  • 拟议的假设测试提供了一种可靠的方法,用于排除药物开发中的临床显著的QTc延长.
  • 这种统计框架增强了具有复杂药理动力学和药理动力学特征的药物的安全性评估.